Commerzbank Ag Analysts Give STADA Arzneimittel AG (SAZ) a €58.00 Price Target

Commerzbank Ag set a €58.00 ($68.24) price target on STADA Arzneimittel AG (ETR:SAZ) in a report issued on Wednesday morning. The brokerage currently has a sell rating on the stock.

Several other equities research analysts also recently commented on SAZ. Warburg Research set a €66.00 ($77.65) price objective on STADA Arzneimittel AG and gave the company a sell rating in a report on Saturday, May 20th. Independent Research GmbH set a €66.00 ($77.65) price objective on STADA Arzneimittel AG and gave the company a neutral rating in a report on Saturday, May 20th. S&P Global set a €66.00 ($77.65) price objective on STADA Arzneimittel AG and gave the company a neutral rating in a report on Saturday, May 20th. Finally, Kepler Capital Markets set a €62.50 ($73.53) price objective on STADA Arzneimittel AG and gave the company a sell rating in a report on Thursday, June 22nd. Two research analysts have rated the stock with a sell rating and three have issued a hold rating to the stock. The stock currently has an average rating of Hold and an average target price of €64.55 ($75.94).

STADA Arzneimittel AG (ETR SAZ) opened at 72.00 on Wednesday. STADA Arzneimittel AG has a 52-week low of €41.40 and a 52-week high of €72.54. The company has a market cap of €4.48 billion and a price-to-earnings ratio of 47.59. The stock has a 50 day moving average of €64.86 and a 200-day moving average of €61.34.

TRADEMARK VIOLATION NOTICE: “Commerzbank Ag Analysts Give STADA Arzneimittel AG (SAZ) a €58.00 Price Target” was originally published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/commerzbank-ag-analysts-give-stada-arzneimittel-ag-saz-a-58-00-price-target.html.

About STADA Arzneimittel AG

Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products.

Analyst Recommendations for STADA Arzneimittel AG (ETR:SAZ)

Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply